Recent updates
from Arcutis Canada

May 28, 2024

Arcutis Canada Submission for Roflumilast Cream 0.15% Accepted for Review by Health Canada for the Treatment of Atopic Dermatitis in Adults and Children 6 Years of Age and Older
Read More

January 8, 2024

Arcutis Canada Announces Health Canada Acceptance of the Supplement to a New Drug Submission for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals 9 Years of Age and Older
Read More

May 1, 2023

Steroid-Free Next Generation Topical Cream ZORYVE Approved by Health Canada to Treat Plaque Psoriasis Anywhere on the Body
Read More

Meaningful innovation
at a glance.

Download our corporate fact sheet intended for investors and shareholders.

Download

 (833) 427‑2884
 canada@arcutis.com

© 2024 Arcutis Canada, Inc. All rights reserved.
This site is intended only for residents of Canada.
CA-CRP-NON-00002 05/23
You are now leaving the Arcutis.ca website.

The information on the website you are about to enter may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries. You are solely responsible for your interactions with that website.

The fact sheet is intended for shareholders and investors.

Before you download the Arcutis corporate fact sheet, please note that marketing authorizations and availability of products may differ between Canada and other countries.

Please note that the information in the environment, social, and governance (ESG) report you are about to download is US based. Marketing authorizations and availability of products may differ between Canada and other countries.

Cancel Continue Download Fact Sheet Download ESG Report